Financial Performance - The company's operating revenue for 2024 reached ¥925,394,524.96, representing a 9.10% increase compared to ¥848,190,443.30 in 2023[27]. - The net profit attributable to shareholders for 2024 was ¥317,822,381.76, a 2.46% increase from ¥310,184,878.02 in 2023[27]. - The cash flow from operating activities decreased by 31.31% to ¥262,440,005.22 in 2024, down from ¥382,075,662.45 in 2023[27]. - The total assets at the end of 2024 amounted to ¥2,709,124,934.20, reflecting a 5.74% increase from ¥2,562,166,715.87 at the end of 2023[27]. - The company reported a basic earnings per share of ¥0.6070 for 2024, up 2.46% from ¥0.5924 in 2023[27]. - The company’s net profit after deducting non-recurring gains and losses was ¥306,309,299.41 in 2024, a 2.72% increase from ¥298,209,749.14 in 2023[27]. - The weighted average return on equity for 2024 was 13.89%, down from 14.96% in 2023[27]. - The company achieved a revenue of ¥925,394,524.96, representing a year-over-year growth of 9.10%[54]. - The net profit attributable to shareholders was ¥317,822,381.76, reflecting a year-over-year increase of 2.46%[54]. Dividend Distribution - The company plans to distribute a cash dividend of 1.20 RMB per 10 shares to all shareholders, based on a total of 523,584,000 shares[11]. - The company aims to improve human quality of life and extend healthy lifespan, with a goal of distributing over 30% of net profit as cash dividends annually since its listing, totaling over 850 million RMB, equivalent to approximately 4 times the initial fundraising amount[101]. - The company has distributed cash dividends exceeding 850 million RMB since its listing, reflecting its commitment to shareholder returns[101]. - The company plans to distribute cash dividends of ¥1.00 per 10 shares for the first three quarters of 2024, based on a total share capital of 523,584,000 shares[199]. - The cash dividend distribution plan for 2024 has been approved by the board and is in compliance with relevant laws and regulations[172]. Product Development and Innovation - The main product, "Dust Mite Drops," significantly contributes to revenue, indicating a high dependency on this product for profitability[9]. - The company aims to accelerate the promotion of new products like "Artemisia Flower Pollen Sublingual Drops" to diversify its product offerings and reduce concentration risk[10]. - The company is actively expanding into the field of natural medicines, focusing on the discovery of new structures and molecules to combat antibiotic-resistant bacteria, addressing a significant public health challenge[44]. - The company has received approval for three new skin prick test solutions: "Sycamore pollen allergen skin prick solution," "German cockroach allergen skin prick solution," and "cat dander allergen skin prick solution," enhancing its product offerings for allergy diagnosis[46]. - The company is focusing R&D investments on its core business while exploring complementary technologies to maintain competitive advantages in allergy treatment[119]. - The company has initiated clinical trials for new products, including a dermatitis diagnostic patch and a dust mite membrane agent, to address specific allergic conditions[119]. Regulatory Environment and Compliance - Regulatory changes in the pharmaceutical industry are tightening, requiring companies to enhance their quality management systems[5]. - The company is committed to compliance and risk management in response to evolving industry regulations[6]. - The company is facing increasing regulatory scrutiny in the pharmaceutical industry, necessitating a robust quality management system[105]. - The company management will closely monitor industry policy changes to mitigate operational risks[106]. - The NMPA has issued multiple guidelines for stem cell products, indicating a commitment to improving the regulatory environment and quality management in the sector[39][40]. Market Position and Strategy - The company plans to leverage the growing health management services and aging population trends to enhance its market position in the biopharmaceutical industry[36]. - The Chinese pharmaceutical market is experiencing rapid growth, driven by increased policy support, rising disposable income, and improved healthcare infrastructure[37]. - The company remains a leader in the sublingual immunotherapy market, with only its products "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops" approved for nationwide sale[42]. - The company is focused on maintaining stable pricing strategies in response to significant bidding price reductions in certain regions[7]. - The company is committed to maintaining its leading position in the desensitization field while exploring new major medical product areas, such as stem cell therapy and natural drugs[102]. Research and Development - The company achieved a total R&D investment of ¥124,764,619.17, accounting for 13.48% of its operating revenue[60]. - The company has nearly 300 R&D personnel, providing a strong talent reserve for innovation and development[60]. - The company has a robust R&D team focused on biopharmaceuticals, with a complete independent R&D chain[53]. - The company has 12 valid Chinese invention patents and 3 utility model patents, along with 7 foreign invention patents[60]. - The company has developed an allergen skin prick test reading device to improve diagnostic efficiency for allergic diseases[63]. Environmental Compliance - The company strictly adhered to multiple environmental protection laws and industry standards during its operations[182]. - The company has established comprehensive wastewater and waste gas treatment facilities, ensuring that the discharge of pollutants is below the limits set by the pollution discharge permit[190]. - The company reported no exceedances of the major pollutants during the reporting period[185]. - The company has implemented a strict emergency response plan for environmental incidents, which is updated regularly and practiced annually[191]. - The company has engaged third-party qualified units for the operation and maintenance of wastewater and exhaust treatment facilities[195]. Corporate Governance - The company has received an A rating for information disclosure from the Shenzhen Stock Exchange for three consecutive years[125]. - The company’s governance structure includes a board of directors, supervisory board, and various committees to ensure effective operation and risk management[127]. - The company emphasizes compliance and transparency in its operations, ensuring timely and accurate information disclosure to investors[125]. - The company has a well-defined internal management structure that operates independently from the controlling shareholder and its affiliates[139]. - The company has a structured remuneration decision process involving the Compensation and Assessment Committee and the Board of Directors[153].

Core Viewpoint - The article discusses the significant increase in pollen levels in Beijing due to a warm winter, leading to a surge in allergy cases and a corresponding rise in the demand for allergy medications, indicating a booming market for allergy-related pharmaceuticals [1][8][9]. Industry Overview - The allergy medication market in China is projected to experience rapid growth, potentially exceeding $20 billion by 2030, driven by an increasing patient population and rising awareness of allergy conditions [8][9]. - Currently, there are approximately 500 million patients in China suffering from allergic diseases such as allergic rhinitis, asthma, atopic dermatitis, and chronic obstructive pulmonary disease [8]. Market Dynamics - Recent data shows a 40% year-on-year increase in the purchase of allergy-related medications, with a 127% day-on-day increase in orders since March 20 in Beijing [8]. - Popular allergy medications like Loratadine and its upgraded version Desloratadine have seen significant sales growth, with Loratadine's retail market sales surpassing 7.6 billion yuan in the past five years, maintaining an annual growth rate of over 10% [10][11]. Competitive Landscape - The allergy medication market is characterized by numerous players, primarily traditional pharmaceutical companies that have historically relied on generic drugs [10]. - New entrants are focusing on innovative drug development, including small molecule targeted drugs and biological agents, with over 1,600 clinical trials related to allergies registered globally [12][13]. Emerging Trends - A new biological drug, Dupilumab, has been approved for treating seasonal allergic rhinitis, showing promising results in clinical trials [13]. - The high pricing of biological drugs presents a challenge for patient acceptance, as many patients prefer cost-effective options despite the superior efficacy of these new treatments [15]. Treatment Innovations - Desensitization therapy is gaining attention as a long-term solution for allergies, although it requires a lengthy treatment period [16][17]. - Companies like Iwubio are already seeing sales growth in desensitization products, indicating a potential shift in treatment preferences among patients [17]. Future Outlook - The allergy medication market in China is still in its early stages, with many companies vying for a share of this lucrative sector, awaiting the emergence of the next blockbuster product [19].

证券代码：300357 证券简称：我武生物 公告编号：2025-005 号 临床试验分期：I期临床试验 浙江我武生物科技股份有限公司 关于屋尘螨膜剂 I 期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 日前，浙江我武生物科技股份有限公司（以下简称"公司"）研发的"屋尘 螨膜剂"（以下简称"本品"）在华中科技大学同济医学院附属同济医院完成了 "在中国成人尘螨变应性鼻炎患者中舌下含服'屋尘螨膜剂'的安全性和耐受性 临床研究"的首例受试者入组，正式进入该临床试验。现将有关内容公告如下： 一、基本情况 产品名称：屋尘螨膜剂 注册分类：治疗用生物制品1类 剂型：膜剂 适应症：作为特异性免疫治疗方式，用于尘螨致敏相关的变应性鼻炎（伴或 不伴过敏性结膜炎、过敏性哮喘）的成人患者。 五、风险提示 申办方：浙江我武生物科技股份有限公司 研究单位：华中科技大学同济医学院附属同济医院 二、后续流程 本品正式进入I期临床试验，I期临床试验的结果存在不确定性。本品后续还 将开展II期、III期临床试验、上市许可申请等主要环节后方可上市销售，其进度 与结果 ...

日前，浙江我武生物科技股份有限公司（以下简称"公司"）获得国家药品 监督管理局发出的《受理通知书》，由公司提交的"皮炎诊断贴剂 02 贴"（以 下简称"本品"）药物临床试验申请已获得正式受理。现将有关内容公告如下： 证券代码：300357 证券简称：我武生物 公告编号：2025-004 号 浙江我武生物科技股份有限公司 关于获得皮炎诊断贴剂 02 贴药物临床试验申请 受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 产品名称：皮炎诊断贴剂02贴 注册分类：治疗用生物制品1类 申请事项：境内生产药品注册临床试验 剂型：贴剂 适应症：用于斑贴试验，辅助诊断与卡松、对苯二胺、甲醛致敏相关的变应 性接触性皮炎。 药品注册申请人：浙江我武生物科技股份有限公司 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予 以受理。 二、后续流程 根据《药品注册管理办法》的规定，国家药品监督管理局药品审评中心（以 下简称"药品审评中心"）将对已受理的药物临床试验申请进行审评，对药物临 床试验申请应当自受理之日起六十日内决定是否同意开展，并通 ...

浙江我武生物科技股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江我武生物科技股份有限公司（以下简称"公司"）于近日收到浙江省药 品监督管理局下发的公司变更后的《药品生产许可证》，现将相关情况披露如下： 证券代码：300357 证券简称：我武生物 公告编号：2025-003 号 | | | | 变更前具备生产条件的生产范围：自产 | | | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 药品 | 药品 | | | | | | | GMP 符 | GMP 符 | | 生产地址 | | 生产范围 | 生产线名称 | 生产车间名称 | 合性检 | 合性检 | | | | | | | 查编号 | 查范围 | | 浙江省德清县 | | 体 内 诊 断 试 | | 941 原料处理车间、 | | | | | | | 悬铃木花粉点 | | | | | 武康镇志远北 | | 剂（悬铃木花 | 刺液生产线 | 921 点刺原液车间、 | | | | 路 636 ...

浙江我武生物科技股份有限公司 会计师事务所选聘制度 （2025 年 2 月） 第一章 总 则 第一条 为了规范浙江我武生物科技股份有限公司（以下简称"公司"）选聘 会计师事务所相关行为，切实维护股东利益，提高财务信息质量，保证财务信息 的真实性和连续性，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》、《国有企业、上市公司选聘会计师 事务所管理办法》、《浙江我武生物科技股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司实际情况，制定本制度。 第二条 公司选聘执行会计报表审计业务的会计师事务所相关行为，应当遵 照本制度。 第三条 公司选聘会计师事务所应当由审计委员会审议同意后，提交董事会 审议，并由股东会决定。公司聘用会计师事务所必须由股东会决定，董事会不得 在股东会决定前委任会计师事务所。 第四条 公司控股股东、实际控制人不得在公司董事会、股东会审议前，向公 司指定会计师事务所。 第二章 选聘会计师事务所执业质量要求 第五条 公司选聘会计师事务所应当具备下列条件： （一 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-002 号 浙江我武生物科技股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十一 次会议通知于 2025 年 2 月 8 日以邮件方式发出。会议于 2025 年 2 月 13 日在公 司上海分公司会议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会 议应出席董事 6 人，实际出席董事 6 人。会议由董事长胡赓熙先生召集并主持， 公司部分监事、高级管理人员列席了会议。本次会议的召集、召开符合《中华人 民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定。 二、董事会会议审议情况 经与会董事认真审议，通过如下决议： 1. 审议通过《关于聘任公司副总经理的议案》 经提名委员会提名，董事会同意聘任HU MUSHUANG（胡沐霜）女士（简 历见附件）为公司副总经理，任期自本次董事会会议审议通过之日起至第五届董 事会期满日止。 本 ...

证券代码:300357 证券简称:我武生物 3. 公司是否会考虑开拓海外市场？ 答：目前，在变应原制品产品线方面，公司专注国内市场。 4. 脱敏治疗的周期一般是多少？ 答：根据《中国变应性鼻炎诊断和治疗指南（2022 年，修订 版）》，变应性鼻炎的过敏原免疫治疗（脱敏治疗）的总疗程为 3 年。 5. 公司新产品有何期待？ 答：2024 年 12 月，由公司提交注册的"悬铃木花粉变应原皮 肤点刺液"、"德国小蠊变应原皮肤点刺液"、"猫毛皮屑变应 原皮肤点刺液"3 项点刺液品种上市许可申请获得批准，与公司 已上市的"粉尘螨皮肤点刺诊断试剂盒"、"屋尘螨皮肤点刺诊断 试剂盒"、"黄花蒿花粉变应原皮肤点刺液"、"白桦花粉变应原皮 肤点刺液"、"葎草花粉变应原皮肤点刺液"产品互为补充，可以 满足更多过敏性疾病患者的过敏原检测需求。 浙江我武生物科技股份有限公司投资者关系活动记录表 编号: 2025-001 | 投资者关系活 | ▪特定对象调研 口分析师会议 后媒体采访 | | --- | --- | | 动类别 | o业绩说明会 ロ新闻发布会 o路演活动 | | | 曰现场参观 ロ其他 | | 参与单位名称 | 海通证 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-001 号 浙江我武生物科技股份有限公司 2024 年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案的情况 1、浙江我武生物科技股份有限公司（以下简称"公司"）2024年前三季度权 益分派方案已获2024年12月6日召开的公司2024年第一次临时股东大会审议通过， 以公司总股本523,584,000股为基数，向全体股东每10股派1.00元人民币现金（含 税），不送红股，不进行资本公积金转增股本。若在分配方案实施前，公司总股 本由于可转债转股、股份回购、股权激励行权或再融资新增股份上市等原因发生 变化的，将按照分红总金额固定不变的原则，调整计算分配比例。 2、自本次分配方案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案一致。 4、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 二、本次实施的利润分配方案 公司2024年前三季度权益分派方案为：以公司现有总股本523,584,000股为基 ...

证券时报e公司讯，①一品红：全资子公司一品红制药自主研发的创新药APH01727片获得美国FDA临床 试验批准，产品拟用于2型糖尿病的治疗。 ②我武生物：获得"悬铃木花粉变应原皮肤点刺液"、"德国小蠊变应原皮肤点刺液"、"猫毛皮屑变应原 皮肤点刺液"3项点刺液品种药品注册证书。 ...